Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications

(2010) Michael A. Nauck   AMERICAN JOURNAL OF MEDICINE

Effect of the artificial sweetener, sucralose, on small intestinal glucose absorption in healthy human subjects

(2010) Jing Ma et al.   BRITISH JOURNAL OF NUTRITION

Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: Relationship to glycemia*

(2010) Adam M. Deane et al.   CRITICAL CARE MEDICINE

Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions

(2010) L. Pala et al.   DIABETIC MEDICINE

Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes

(2010) Erin L St Onge et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Endogenous GLP-1 Regulates Postprandial Glycemia in Humans: Relative Contributions of Insulin, Glucagon, and Gastric Emptying

(2010) Mathias Nicolaus et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors

(2010) A. Amato et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion

(2010) Anne-Barbara Witte et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Diabetic Gastroparesis

(2009) Jing Ma et al.   DRUGS

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes

(2009) M. A. Nauck et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia

(2009) Adam M. Deane et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GLP-1 regulates gastroduodenal motility involving cholinergic pathways

(2009) j. schirra et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study

(2008) P. M. HELLSTRÖM et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study

(2008) Adrian Vella et al.   CLINICAL ENDOCRINOLOGY

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

(2008) Ralph A. DeFronzo et al.   CURRENT MEDICAL RESEARCH AND OPINION

Regulation of Islet Hormone Release and Gastric Emptying by Endogenous Glucagon-Like Peptide 1 after Glucose Ingestion

(2008) Marzieh Salehi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome

(2008) p. m. hellström et al.   NEUROGASTROENTEROLOGY AND MOTILITY

The Role of Incretins in Glucose Homeostasis and Diabetes Treatment

(2008) W. Kim et al.   PHARMACOLOGICAL REVIEWS

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

(2008) Helle Linnebjerg et al.   REGULATORY PEPTIDES

Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans

(2007) H.-J. Woerle et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM